Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 19, 2021 06:30 ET | Source: Beam Therapeutics

Beam Therapeutics Inc. Announces $260 Million Common Stock Investment from Multiple Investors

CAMBRIDGE, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM) (the “Company”), a biotechnology company developing precision genetic medicines through base editing, today...
January 11, 2021 06:30 ET | Source: Beam Therapeutics

Beam Therapeutics Appoints Leading Healthcare Executive Kate Walsh to its Board of Directors

CAMBRIDGE, Mass., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...
January 05, 2021 06:30 ET | Source: Beam Therapeutics

Beam Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...
December 05, 2020 07:00 ET | Source: Beam Therapeutics

Beam Therapeutics Presents Updated Data from Novel Base Editing Programs for Sickle Cell Disease at ASH 2020

BEAM-101 Data Highlight Precision of Base Editor with No Off-Target Editing Observed; Will Support Planned IND Submission in the Second Half of 2021 In Vivo Data from Makassar Base Editing Program...
November 20, 2020 16:01 ET | Source: Beam Therapeutics

The Boston Globe Names Beam Therapeutics a Top Place to Work for 2020

CAMBRIDGE, Mass., Nov. 20, 2020 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today has been named...
November 13, 2020 08:00 ET | Source: Beam Therapeutics

Beam Therapeutics Presents First Data Highlighting Base Editing Program for Glycogen Storage Disease Type Ia at AASLD

Novel Base Editors for Two Most Common GSDIa Mutations Demonstrate Significantly Higher Levels of In Vivo Mutation Correction than Required to Restore Glucose Homeostasis Previously Presented Data...
November 10, 2020 06:30 ET | Source: Beam Therapeutics

Beam Therapeutics Announces Business and Pipeline Progress and Reports Third Quarter 2020 Financial Results

BEAM-201, an Off the Shelf Allogeneic CD7-Targeting CAR-T, Named as Development Candidate for Treatment of T-ALL; First Cell Therapy Featuring Four Simultaneous Genetic Edits; Demonstrates 96-99%...
November 09, 2020 08:15 ET | Source: Beam Therapeutics

Beam Therapeutics Names First CAR-T Base Editing Development Candidate for the Treatment of T-ALL and Presents New Data at SITC 2020

BEAM-201, an Off the Shelf Allogeneic CD7-Targeting CAR-T, Named as Development Candidate for Treatment of T-Cell Acute Lymphoblastic Leukemia First Cell Therapy Featuring Simultaneous Edits to Four...
October 02, 2020 08:00 ET | Source: Beam Therapeutics

Beam Therapeutics to Participate in Chardan Virtual 4th Annual Genetic Medicines Conference

CAMBRIDGE, Mass., Oct. 02, 2020 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...
September 30, 2020 20:46 ET | Source: Beam Therapeutics

Beam Therapeutics Announces Pricing of Public Offering of Common Stock

CAMBRIDGE, Mass., Sept. 30, 2020 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the...